167. La seule declaration citee dan

167. La seule declaration citee dans la Decision emanant d'un employe de Sanofi-Aventis France concerne le propos suivant tenu par une deleguee pharmaceutique :

« Un patient qui fait un syndrome coronaire, c'est un patient qui a un haut risque de recidiver ou de mourir. Plavix a fait l'objet d'essais cliniques. Par rapport aux generiques, qui n'auraient pas (au
conditionnel, car a l'epoque nous ne connaissions pas tous les generiques) toutes les indications,
cela permet au patient d'avoir le traitement de reference. »79

Résultats (Anglais) 1:

167. the only statement cited in the decision emanating from an employee of sanofi-aventis France concerned about the next run by a pharmaceutical Representative:

"a patient who is a coronary syndrome, this is a patient who has a high risk to reoffend or die. plavix has been the subject of clinical trials. compared to generic, which would not (conditional
,as was the era we do not know all the Internet) all indications
it allows the patient to have the treatment of reference. "79

Résultats (Anglais) 2:

167. The only statement quoted in Decision emanating from an employee of Sanofi - Aventis France concerns the following remarks by a pharmaceutical delegate:

a patient making a coronary syndrome, it is a patient who has a high risk of given or die. Plavix has been the subject of clinical trials. Compared to generics, that would not (in the
conditional,) because at the time we knew not all generics) all indications,
this allows the patient to have the standard treatment. ' 79
.

Résultats (Anglais) 3:

167. The only statement quoted in the Decision from an employee of Sanofi-Aventis France concerned about the next held by a delegate pharmaceutical:

"a patient who makes a coronary syndrome, this is a patient who has a high risk to reoffend or die. Plavix has been the subject of clinical trials. In relation to the generic, which would not (at
conditional,Because at the time we did not know all the generic) all indications,
This allows the patient to have the reference treatment. " 79